IGF1 and Miyoshi myopathy: We therefore first examined whether NCP26 maintains its anti-proliferative effect against MM cells in the presence of exogenous IL-6 or IGF-1 and found that neither impacted NCP26’s effects on the AMO1 and RPMI 8226 cell lines, as assessed by BrdU uptake (Fig. 3B).